medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (1)

Quick guideline to keloid scar management

Angulo RA, Alcalá PD

Language: Spanish
References: 36
Page: 39-45
PDF size: 247.88 Kb.


ABSTRACT

Keloid scars are fibroproliferative disorders derived from an alteration in the healing process. To date, there are no international guidelines for their management, reason why sometimes they become a therapeutic challenge. We review the recent literature including the noninvasive, injectable, and surgical treatments available, with the aim of providing a quick treatment guideline. We present a flowchart displaying keloid scar management practiced by the authors.


REFERENCES

  1. Wu W, Zhao Y, Chen Y et al., Comparing the efficacy of multipledrugs injection for the treatment of hypertrophic scars andkeloid: a network meta-analysis, Aesthetic Plast Surg 2023;47(1):465-472. doi: 10.1007/s00266-022-03163-4.

  2. Thornton NJ, García BA, Hoyer P et al., Keloid scars: an updatedreview of combination therapies, Cureus 2021; 13(1):e12999.doi: 10.7759/cureus.12999.

  3. Liu R, Xiao H, Wang R et al., Risk factors associated with the progressionfrom keloids to severe keloids, Chin Med J (Inglaterra)2022; 5:135(7):828-36. doi: 10.1097/CM9.0000000000002093.

  4. Limandjaja GC, Niessen FB, Scheper RJ et al., The keloiddisorder: heterogeneity, histopathology, mechanisms andmodels, Front Cell Dev Biol 2020; 26:8:360. doi: 10.3389/fcell.2020.00360.

  5. Sadiq A, Khumalo NP y Bayat A, Genetics of keloid scarring.Textbook on scar management: state of the art managementand emerging technologies, Cham, Springer, 2020, 8. pmid:36351116.

  6. Brown JJ, Ollier WE, Thomson W et al., Positive association ofhla-drb1*15 with keloid disease in Caucasians, Int J Immunogenet2008; 35(4-5):303-7. doi: 10.1111/j.1744-313X.2008.00780.x.

  7. Ogawa R, Okai K, Tokumura F et al., The relationship betweenskin stretching/contraction and pathologic scarring:the important role of mechanical forces in keloid generation,Wound Repair Regen 2012; 20(2):149-57. doi: 10.1111/j.1524-475X.2012.00766.x.

  8. Ogawa R y Akaishi S, Endothelial dysfunction may play a keyrole in keloid and hypertrophic scar pathogenesis: keloids andhypertrophic scars may be vascular disorders, Med Hypotheses2016; 96:51-60. doi: 10.1016/j.mehy.2016.09.024.

  9. Berman B, Maderal A y Raphael B, Keloids and hypertrophicscars: pathophysiology, classification, and treatment,Dermatol Surg 2017; 43 Suppl 1:S3-18. doi: 10.1097/DSS.0000000000000819.

  10. Rousselle P, Montmasson M y Garnier C, Extracellular matrixcontribution to skin wound re-epithelialization, Matrix Biol 2019;75-76:12-26. doi: 10.1016/j.matbio.2018.01.002.

  11. Butzelaar L, Niessen FB, Talhout W et al., Different properties ofskin of different body sites: the root of keloid formation?, WoundRepair Regen 2017; 25(5):758-66. doi: 10.1111/wrr.12574.

  12. Yin Q, Niessen FB, Gibbs S et al., Intralesional corticosteroid administrationin the treatment of keloids: a survey among Dutchdermatologists and plastic surgeons, J Dermatolog Treat 2023;34(1):2159308. doi: 10.1080/09546634.2022.2159308.

  13. Limandjaja GC, Niessen FB, Scheper RJ et al., Hypertrophicscars and keloids: overview of the evidence and practical guidefor differentiating between these abnormal scars, Exp Dermatol2021; 30(1):146-61. doi: 10.1111/exd.14121.

  14. Ud-Din S. y Bayat A, Strategic management of keloid disease inethnic skin: a structured approach supported by the emergingliterature, The British Journal of Dermatology 2013; 169(3):71.81.Disponible en: https://doi.org/10.1111/bjd.12588.

  15. Bran GM, Goessler UR, Hormann K et al., Keloids: current conceptsof pathogenesis (review), Int J Mol Med 2009; 24(3):283-93. doi: 10.3892/ijmm_00000231.

  16. Ogawa R, Keloid and hypertrophic scars are the result ofchronic inflammation in the reticular dermis, Int J Mol Sci 2017;18(3):606. doi: 10.3390/ijms18030606.

  17. Ogawa R, Akaishi S y Hyakusoku H, Differential and exclusivediagnosis of diseases that resemble keloids and hypertrophicscars, Ann Plast Surg 2009; 62(6):660-4. doi: 10.1097/SAP.0b013e31817e9d67.

  18. Ogawa R, Keloids and hypertrophic scars, UpToDate 2022: 1-35.Disponible en: https://www.uptodate.com/contents/keloidsand-hypertrophic-scars.

  19. Kim SW, Management of keloid scars: noninvasive and invasivetreatments, Arch Plast Surg 2021; 48(2):149-57. doi: 10.5999/aps.2020.01914.

  20. Puri N y Talwar A, The efficacy of silicone gel for the treatmentof hypertrophic scars and keloids, J Cutan Aesthet Surg 2009;2(2):104-6. doi: 10.4103/0974-2077.58527.

  21. Heppt MV, Breuninger H, Reinholz M et al., Current strategiesin the treatment of scars and keloids, Facial Plastic Surgery2015; 31(4):386-95. doi:10.1055/s-0035-1563694.

  22. Barone N, Safran T, Vorstenbosch J et al., Current advances inhypertrophic scar and keloid management, Semin Plast Surg2021; 35(3):145-52. doi: 10.1055/s-0041-1731461.

  23. Ekstein SF, Wyles SP, Moran SL et al., Keloids: a review of therapeuticmanagement, Int J Dermatol 2021; 60(6):661-71. doi:10.1111/ijd.15159.

  24. Khalid FA, Mehrose MY, Saleem M et al., Reply to commentson “comparison of efficacy and safety of intralesional triamcinoloneand combination of triamcinolone with 5-fluorouracil in thetreatment of keloids and hypertrophic scars: randomised controltrial”, Burns 2020; 46(2):491-2. doi: 10.1016/j.burns.2018.12.014.

  25. Moravej H, Forghanian A, Dadkhahfar S et al., Intralesional bleomycinversus intralesional triamcinolone in the treatment of keloidsand hypertrophic scars, Dermatol Ther 2022; 35(9):e15730.doi: 10.1111/dth.15730.

  26. Gauglitz GG, Korting HC, Pavicic T et al., Hypertrophic scarringand keloids: pathomechanisms and current and emerging treatmentstrategies, Mol Med 2011; 17(1-2):113-25. doi: 10.2119/molmed.2009.00153.

  27. Thornton NJ, García BA, Hoyer P et al., Keloid scars: an updatedreview of combination therapies, Cureus 2015; 13(1):e12999.doi: 10.7759/cureus.12999.

  28. Chan LJ y Greenberg HL, Establishment of an efficacioustreatment period for prophylaxis of auricular keloid recurrencepostexcision using topical imiquimod 5%: a demonstrativecase series, jaad Case Rep 2022; 30(26):41-4. doi: 10.1016/j.jdcr.2022.06.012.

  29. Betarbet U y Blalock TW, Keloids: a review of etiology, prevention,and treatment, J Clin Aesthet Dermatol 2020; 13(2):33-43.

  30. Mari W, Alsabri SG, Tabal N et al., Novel insights on understandingof keloid scar: article review, J Am Coll Clin Wound Spec2016; 7(1-3):1-7. doi: 10.1016/j.jccw.2016.10.001.

  31. Arno AI, Gauglitz GG, Barret JP et al., Up-to-date approach tomanage keloids and hypertrophic scars: a useful guide, Burns2014; 40(7):1255-66. doi: 10.1016/j.burns.2014.02.011.

  32. Litrowski N, Boullie MC, Dehesdin D et al., Treatment of earlobekeloids by surgical excision and cryosurgery, J Eur Acad DermatolVenereol 2014; 28(10):1324-31. doi: 10.1111/jdv.12282. Epub2013 Oct 3. PMID: 24118593.

  33. Chen F, Kuo YR, Huang CJ et al., Lesion site is the key prognosticfactor for keloid patients receiving surgery with adjuvantradiotherapy, Ann Plast Surg 2022; 89(6):626-30. doi: 10.1097/SAP.0000000000003315.

  34. Garg GA, Sao PP y Khopkar US, Effect of carbon dioxide laserablation followed by intralesional steroids on keloids, J CutanAesthet Surg 2011; 4(1):2-6. doi: 10.4103/0974-2077.79176.

  35. Limmer EE y Glass DA Jr, A review of current keloid management:mainstay monotherapies and emerging approaches,Dermatol Ther (Heidelberg) 2020; 10(5):931-48. doi: 10.1007/s13555-020-00427-2.

  36. Jacobs C y Wilmink J, Combined versus single treatment regimensfor keloid therapy using serial intralesional corticosteroidinjections, surgical excision, silicone and/or cryotherapy, jprasOpen 2021; 29:157-66. doi: 10.1016/j.jpra.2021.05.011.




2020     |     www.medigraphic.com